This chapter should be cited as follows: This chapter was last updated:
Verlinsky, Y, Kuliev, A, Glob. libr. women's med.,
(ISSN: 1756-2228) 2008; DOI 10.3843/GLOWM.10373
January 2008

Assisted reproductive technology

Preimplantation Diagnosis for Mendelian Disorders

Yury Verlinsky, MD
Reproductive Genetics Institute, Chicago, Illinois 60657, USA
Anver Kuliev, MD
Reproductive Genetics Institute, Chicago, Illinois 60657, USA


PGD (preimplantation genetic diagnosis) has become an established procedure for avoiding the birth of affected children with single gene disorders and having a healthy unaffected offspring of their own. PGD is performed through polar body or embryo biopsy, which have no deleterious effect on the pre- and post-implantation development. The review describes recent developments in improving the accuracy of PGD for Mendelian disorders, and current changes in the spectrum of conditions for which PGD has been applied. Among the most recent applications of PGD were PGD for congenital malformations, blood group incompatibility, and increasing numbers of late onset disorders with genetic predisposition, which have never been indications for prenatal diagnosis. Despite ethical concerns, PGD has been further applied for preselection of unaffected and HLA matched embryos, and also for preimplantation HLA matching without testing for causative gene. This extends the practical value of PGD, with its utility being no longer limited to prevention of single gene disorders, but expanded to treatment of siblings requiring stem cell transplantation. 

PGD is a novel approach to detect genetic disorders before pregnancy, avoiding the need for prenatal diagnosis and abortion. It is based on testing of oocytes or embryos to pre-select and transfer only normal embryos back to the patient, achieving an unaffected pregnancy and birth of a healthy child. PGD is performed either by testing single blastomeres or a few trophectoderm cells removed from preimplantation embryos, or by testing female gametes  (Fig. 1).1, 2 The latter is based on the removal and genetic analysis of the first and second polar bodies (PB1 and PB2), which represent the byproducts of the first and second meiotic divisions (see Fig. 1A, 1B, 1C). Because neither PB1 nor PB2 have any biologic significance for embryo development, they may be removed and tested for the genetic contents to predict the resulting maternal contribution to the embryo. However, this approach cannot be applied for testing of paternally derived abnormalities, and gender determination, which may be detected by genetic analysis of single blastomeres or trophectoderm cells, removed from preimplantation embryos (see Fig. 1D). Both methods, therefore, are complementary and may be applied depending on the PGD objectives in each patient.

Figure 1. A. First polar body removal. B. Second polar body removal. C. First and second polar body removal. D. Blastomere biopsy.

More than 30,000 PGD cycles have been performed and resulted in the birth of thousands of children following the procedure.3, 4 The overall experience of using PGD for single gene disorders is presently almost 1500 cases, showing that it is an established alternative to traditional prenatal diagnosis, which may be reliably applied as an integral part of genetic practices.4, 5, 6, 7, 8 As will be demonstrated, PGD has appeared to be applicable to a wider range of inherited conditions which have never been indications for prenatal diagnosis, and also made it possible to initiate nondisease testing to preselect HLA-compatible offspring in addition to PGD for causative gene, which makes it possible to facilitate treatment of siblings requiring stem cell transplantation.


Sources for Misdiagnosis

Because PGD for single gene disorders is based on single cell genetic analysis, its accuracy largely depends on the limitations of single cell DNA analysis, which may potentially cause misdiagnosis (Table 1). One of the key contributors to misdiagnosis is the phenomenon of preferential amplification, also known as allele-specific amplification failure (allele drop out-ADO), requiring the application of special protocols to ensure the highest ADO detection rate (Fig. 2).1, 2, 9 A A few previously reported misdiagnoses, involving PGD for beta-thalassemia, myotonic dystrophy (DM), fragile-X syndrome (XMR1) and cystic fibrosis (CF), might have been due to this phenomenon, which has not initially been fully realized.5, 7

Table 1. Problems of PGD for single gene disorders

Prevention and elimination of DNA contamination
Optimization of reaction conditions
Detection of allele drop-out (ADO) and preferential amplification
Detection of aneuploidy



Figure 2. Detection by linked markers for CFTR N1303 mutation

It has been demonstrated that ADO rates in single cells might be different for different types of heterozygous cells.2, 10 The ADO rate may exceed 20% in blastomeres compared with ADO rate in single fibroblasts and PB1, which was shown to be less than 10% (Fig. 3). A high rate of ADO in blastomeres may lead to an obvious misdiagnosis, especially in compound heterozygous embryos. As mentioned, most misdiagnoses, especially those at the initial stage of application of PGD for single gene disorders, were in the cases of blastomere biopsy from apparently compound heterozygous embryos.

Figure 3. ADO rate in different types of single cells


Use of Polymorphic Markers

To avoid a misdiagnosis caused by preferential amplification, a simultaneous detection of mutant gene together with up to three highly polymorphic markers closely linked to the gene tested was introduced.1, 2, 9 Each additional linked marker reduced misdiagnosis rate approximately by half, so with one linked marker amplified together with mutation, a misdiagnosis risk in blastomere analysis may be reduced from 20% to 10%, with two from 10% to 5% and with three from 5% to practically zero (Fig. 4). So, a multiplex nested polymerase chain reaction (PCR) analysis is performed, with the initial PCR containing all the pairs of outside primers, so that after the first-round PCR, separate aliquots of the resulting PCR product may be amplified using the inside primers specific for each site (Fig. 5). Only when the polymorphic sites and the mutation agree are embryos transferred. So, multiplex amplification allows detecting of ADO and prevents the transfer of misdiagnosed affected embryos.

Figure 4. ADO detection with application of additional linked markers

Figure 5. Multiplex nested PCR for CFTR G551D mutation


Sequential PB1 and PB2 DNA Analysis

Another efficient approach for avoiding misdiagnosis may be a sequential genetic analysis of the PB1 and PB2 in PGD for maternally derived mutations.1, 2 Detection of both mutant and normal alleles in the heterozygous PB1, together with the mutant allele in the corresponding PB2, leaves no doubt that the resulting maternal contribution to the embryo is normal, even without testing for the linked markers as a control (Fig. 6). However, it will be ideal to test simultaneously at least for one linked marker to confirm the diagnosis.

Figure 6. Principle of preselection of mutation-free oocytes using sequential force and second polar analysis and linked polymorphism in PGD for sickle cell disease

Alternatively, the mutation-free oocytes may be also predicted when corresponding PB1 is homozygous mutant (Fig. 7). In that scenario, the corresponding PB2 should be hemizygous-normal, similar to the resulting maternal pronucleus. However, the genotype of the resulting maternal contribution may be quite opposite, in other words, mutant, if the corresponding PB1 is in fact heterozygous but erroneously diagnosed as homozygous-normal because of ADO of the normal allele. In the aforementioned scenario, the extrusion of the normal allele with PB2 would lead to the mutant allele left in the resulting oocyte. Therefore, the embryos resulting from the oocytes with homozygous mutant PB1 cannot be acceptable for transfer, unless the heterozygous status of PB1 is excluded by the use of linked markers as described. The example of misdiagnosis, caused by ADO of the normal allele in PB1 has been described earlier in a PGD cycle performed for FMR1 (Table 2).11 To completely avoid misdiagnosis, a sequential PB1 and PB2 may be required to combine with multiplex PCR to exclude the possibility of an undetected ADO in heterozygous PB1. The analysis of more than 1000 oocytes tested by sequential PB1 and PB2 analyses showed that more than half of ADOs were detected by sequential analysis of PB1 and PB2, with the remaining cases detected by multiplex PCR.9 The accuracy of this approach may be demonstrated by the reports of PGD for thalassemia and familial dysautonomia (FD), resulting in the transfer of three unaffected embryos in each case, which were confirmed by the birth of the two sets of triplets free from thalassemia and FD (Fig. 8).12, 13

Figure 7. Possible distribution of thalassemia mutation after types I and II meiotic divisions


Table 2. PGD for FMRI gene by linkage analysis in case of misdiagnosis

Oocyte # Cell Type DXs1193 (in bp) DXs548 (in bp) Predicted Oocyte Genotype
1 PB1 154*/156 245/247 Affected
  PB2 156 247  
3 PB1 154/156 245/247 Affected
  PB2 156 247  
5 PB1 154/156 245/247 Normal
  PB2 154 245  
6 PB1 154/156 245/247 Normal
  PB2 154 245  
9 PB1 154 245 Normal
  PB2 156 247  
10 PB1 154/156 245/247 Affected
  PB2 156 247  
Cord blood   154 245 Affected

PB 1 first polar body; PB 2 second polar body; Bp, size of PCR product in base pairs.
*Bold figures show markers linked to the expanded allele.
†Potential 5% risk for ADO (allele drop-out)


Fig. 8. Family pedigree. PGD for familial dysautonomia resulting in birth of triplets free from disease


Fluorescent and Real Time PCR

The other method with the proved potential for detecting and avoiding misdiagnosis caused by preferential amplification is fluorescence PCR (F-PCR), which may allow detection of some of the heterozygous PB1 or blastomeres misdiagnosed as homozygous in conventional PCR, therefore having potential of reducing the ADO rates at least to some extent (Fig. 9).9 In addition, the method also allows a simultaneous gender determination, DNA fingerprinting, and detection of common aneuploidies. With further improvement and simplification, F-PCR combined with a multiplex system and sequential PB1 and PB2 analysis in cases of maternally derived mutations may allow excluding almost completely the risk for misdiagnosis caused by preferential amplification.

Figure 9. Comparison of ADO rates after fluorescent or conventional PCR

The accuracy of PGD has been further improved with the application of fluorescent PCR with the expand long template (ELT) kit, which enabled reduction of the ADO rate from as high as 30–35% in both conventional and fluorescent PCR to as low as 5% in testing for DM.14 Another development in improving the accuracy of single cell PCR analysis involves the application of real-time PCR, which was found to reduce the ADO rate almost by half, compared with conventional or fluorescent PCR2. The application of these approaches together with simultaneous testing for the causative mutation along with at least one or two linked markers may allow avoiding reliably the risk for misdiagnosis.


Simultaneous Testing for Aneuploidy

Finally, because of high rate of mosaicism at the cleavage stage, testing for the chromosome, in which the gene in question is mapped, is of an obvious value to exclude the lack of mutant allele caused by monosomy of this chromosome in the biopsied blastomere. As mentioned, aneuploidy testing is technically feasible and may be performed by adding primers for chromosome-specific microsatellite markers to the multiplex PCR protocols worked out for specific genetic disorders.15 The development of multiplex nested PCR systems will also allow performing PGD for different conditions simultaneously, as attempted for CFTR mutation together with XMR1 or gender determination, for two different conditions when the couples are at risk for producing the offspring with more than one genetic disease.16, 17, 18, 19 Simultaneous detection of different genetic conditions and aneuploidy may in future become routine with the progress of single cell microarray technology.20


Custom-Made PGD Design

Because of the need for the development of a custom-made PGD design for each mutation and each couple, a preparatory work has become an integral part of PGD for single gene disorders to ensure avoiding the potential misdiagnosis. For example, in some cases a particular set of outside primers has to be designed to eliminate false priming to the pseudogene, as described in PGD for long-chain 3-hydroxyacyl-Coa dehydrogenase deficiency (Fig. 10).21 Also, the preparatory work may frequently involve a single sperm-typing needed for establishing paternal haplotypes so that linked marker analysis could be performed in addition to mutation analysis, especially in cases of paternally derived dominant conditions or PGD combined with preimplantation HLA-matching (see later). The availability of the parental haplotypes allows not only the confirmation of the absence of the mutant gene but also the presence of both maternal and paternal wild alleles in PGD by blastomere analysis, especially when only one informative marker is available, as demonstrated in PGD for sonic hedgehog mutation (Table 3).22

Figure 10. PGD for long-chain 3-hydoxyacyl-CoA dehydrogenase deficiency


Table 3. Results of multiplex PCR analysis with simultaneous testing for SHH mutation and linked marker (D7S550) and the follow up embryo analysis for confirmation of single blastomere diagnosis

Embryo # Mutation Analysis (SHH gene) Linked Marker Analysis (D7S550)* Predicted Genotype Transfer/Follow-Up Analysis
2 N/ADO 2/4 Carrier (affected) Confirmed
4 N/N 1/3 Normal Transferred
5 N/N 1/3 Normal Transferred
8 N/N 2/3 Normal Frozen
9 N/ADO 2/4 Carrier (affected) Confirmed
10 ADO/M 1/4 Carrier (affected) Confirmed
16 N/N 2/3 Normal Frozen
17 N/ADO 1/4 Carrier (affected) Confirmed
19 N/ADO 1/4 Carrier (affected) Confirmed
Mother N/N 1/2 Normal  
Father N/M 3/4 Carrier (mosaic)  

N, normal allele; M, mutant allele; ADO, allele dropout.
*Linked markers:
Maternal PCR product 138 base pairs = 1
Maternal PCR product 158 base pairs = 2
Paternal PCR product 152 base pairs = 3 (linked to normal gene)
Paternal PCR product 156 base pairs = 4 (linked to mutant gene)




The list of disorders, presently comprising more than 170 different conditions, for which PGD was applied is being extended beyond the indications for prenatal diagnosis, although the most frequent ones are still CF and hemoglobin disorders (Table 4).5, 7, 23, 24 According to our experience of over thousand PGD cycles for single gene disorders, almost half of these cycles were performed for CF and hemoglobin disorders, followed by DM and XMR1,25 similar to the experiences of the other active centers.7 There have been many previous reports on PGD for different single gene disorders as well extensive reviews on the subject.3, 9, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 So we will present only the most recent developments and the expanding application of PGD, which has been shown to be useful for much wider indications than those used in traditional prenatal diagnosis.

Table 4 List of diseases and genes for which PGD has been performed

DiseaseMIM number  
Gene name/symbolProtein nameLocation 
Achondroplasia; ACH 100800100800
 FGFR3Fibroblast growth factor receptor 3 [precursor] 4 p16.3
Acyl-CoA dehydrogenase, medium-chain, deficiency 201450 AR ACADMAcyl-CoA dehydrogenase, medium-chain specific, mitochondrial [precursor] 1p31 
Acyl-CoA dehydrogenase, very long-chain; ACADVL 609575 AR ACADVLAcyl-coenzyme A dehydrogenase, very long chain 17p13-p11
Adadenosine deaminase deficiency; ADA 102700 AR  ADAAdenosine deaminase 20q13.11
Adenomatous polyposis of the colon; APC 175100 AD  APCAdenomatous polyposis coli protein 5 q21-q22
Adrenoleukodystrophy; ALD 300100
Adrenoleukodystrophy protein
Albinism, ocular, type I; OA1 300500
G-protein coupled receptor 143
Alopecia universalis congenita; ALUNC 203655
Hairless protein
 8 p21.2
Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis 203700
Mitochondrial DNA polymerase gamma
Alpha 1 antitrypsin deficiency (AAT) 107400
Alpha-1-antitrypsin [precursor]
Alport syndrome, X-linked; ATS 301050
AMME syndrome candidate gene 1 protein
Amyloidosis I, hereditary neuropathic 176300
Transthyretin [precursor]
Androgen receptor; AR (testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) 313700
AR protein
Aneuploidies by STR genotyping  
Angioedema, hereditary; HAE 106100
Plasma protease C1 inhibitor precursor
Ataxia-telangiectasia; AT 208900
Serine-protein kinase ATM
Basal cell nevus syndrome; BCNS (Gorlin) 109400
Patched protein homolog 1 9q22.1–31
Blepharophimosis, ptosis, and epicanthus inversus; BPES 110100 AD FOXL2 Forkhead box protein L2  3 q23 
Blood group − Kell−Cellano system 110900 AD KELKell blood group glycoprotein 7 q33
Brachydactyly, Type B1; BDB1 113000 AR ROR2Receptor tyrosine kinase-like orphan receptor 2 9q22
Brain tumor, posterior fossa of infancy, familial 601607  AD  SMARCB1SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily B member  22q11.2  
Breast cancer, familial 113705 AD BRCA1Breast cancer type 1 susceptibility protein 17q21
Breast cancer, familial 600185 AD  BRCA2Breast cancer type 2 susceptibility protein 13q12.3
Bruton agammaglobulinaemia tyrosine kinase; BTK 300300 XL BTKBruton agammaglobulinaemia tyrosine kinase  Xq21.33-q22
Canavan disease 271900 AR ASPAAspartoacylase 17pter-p13
Ceroid lipofuscinosis, neuronal 2, late infantile; CLN2 204500 AR CLN2Tripeptidyl-peptidase I [precursor] 11p15
Charcot−Marie−Tooth disease, axonal, type 2E 607684 AD NEFLNeurofilament triplet L protein 8 p21
Charcot−Marie−Tooth disease, demyelinating, type 1A; CMT1A 118220 AD PMP22Peripheral myelin protein 22  17p12 
Charcot-Marie-Tooth disease, demyelinating, type 1B; CMT1B 118200 AD MPZ Myelin P0 protein [precursor] 1q23.3 
Charcot−Marie−Tooth disease, X-linked, 1; CMTX1 302800 XL GJB1Gap junction beta-1 protein Xq13.1
Cholestasis, progressive familial intrahepatic 2 603201 AR ABCB11ATP-binding cassette, sub-family B (MDR/TAP), member 11 2q24
Chondrodysplasia punctata 1, X-linked recessive; CDPX1 302950 XL ARSEArylsulfatase E Xp22.3
Choroideraemia; CHM 303100 XL CHMRab proteins geranylgeranyltransferase component A 1 Xq21.2
Citrullinaemia, classic 215700 AR ASSArgininosuccinate synthase 9q34.1
Collagen, type IV, alpha-5; COL4A5 303630 XL COL4A5Collagen, type IV, alpha 5 Xq22.3
Colorectal cancer, hereditary non-polyposis, type 1; HNPCC1 120435 AD MSH2DNA mismatch repair protein Msh2 2p 2-p21
Colorectal cancer, hereditary non-polyposis, type 2; HNPCC2 609310 AD MLH1DNA mismatch repair protein Mlh1 3 p21.3
Congenital adrenal hyperplasia (CAH) 201910 AR CYP21A2Cytochrome P450 XXIB 6 p21.3
Craniofacial dysostosis, type I; (CFD1) 123500 AD FGFR2Fibroblast growth factor receptor 2 [precursor] 10q26.13 
Currarino syndrome 176450 AD HLXB9Homeobox protein HB9 7q36
Cutis laxa, autosomal recessive, type I 219100 AR  FBLN4EGF-containing fibulin-like extracellular matrix protein 2 11q13
Cystic fibrosis; CF 219700 AR CFTRCystic fibrosis transmembrane conductance regulator 7q31.2 
Cystinosis, nephropathic; CTNS 219800 AR CTNSCystinosin  17p13
Darier−White disease; DAR 124200 AD ATP2A2Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 12q23-q24.1
Deafness, neurosensory, autosomal recessive 1; DFNB1 220290 AR  GJB2 Gap junction protein connexin-26  13q11-q12
Diamond−Blackfan anaemia; DBA 105650 AD RPS1940S ribosomal protein S19 19q13.2
Dysautonomia, familial 223900 AR IKBKAP  9q31
Dystrophia myotonica 1 160900 AD DMPKMyotonin-protein kinase 19q13.2-q13.3 
Early-onset familial Alzheimer disease 104760 AD APPAmyloid beta A4 protein [precursor] 21q21.3
Ectodermal dysplasia 1, anhidrotic; ED1 305100 XL ED1Ectodysplasin A Xq13.1
Ectodermal dysplasia, anhidrotic 224900 AR EDARTumor necrosis factor receptor superfamily member EDAR [precursor] 2q 11-q13
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 1; EEC1 129900  AD  p63 Tumor protein 63 7 q11.2-q21.3
Emery−Dreifuss muscular dystrophy, autosomal recessive; EDMD3 604929  AR LMNALamin A/C 1q21.2
Emery−Dreifuss muscular dystrophy, X-linked; EDMD 310300 XL EMDEmerin Xq28
Epidermolysis bullosa dystrophica, Pasini type 131750 AR COL7A1Collagen alpha 1(VII) chain [precursor] 3 p21.3
Epidermolysis bullosa lethalis 226650 AR LAMB3Laminin, beta 3 1q32
Epidermolysis bullosa simplex and limb-girdle muscular dystrophy 226670 AR PLEC1Plectin 1, intermediate filament binding protein 500kDa  8q24
Epiphyseal dysplasia, multiple, 1; EDM1 132400 AD COMPCartilage oligomeric matrix protein [precursor]  19p13.1
Exostoses, multiple, type I 133700 AD EXT1Exostosin-1 8 q24.11q24.13
Fabry disease 301500 XL GLAAlpha-galactosidase A [precursor] Xq22
Facioscapulohumeral muscular dystrophy 1A; FSHMD1A 158900 AD FRG1FRG1 protein 4 q35
Fanconi anaemia, complementation group C; FANCC 227645 AR FANCCFanconi anaemia group C protein 9q22.3
Fanconi anaemia, complementation group E; FANCE 600901 AR FANCEFanconi anaemia, complementation group E 6p22-p21
Fanconi anaemia, complementation group F; FANCF 603467  AR FANCFFanconi anaemia group F protein 11p15
Fanconi anaemia, complementation group G 602956 AR XRCC9 DNA-repair protein XRCC9
Fanconi anaemia, complementation group J 609054 AR BRIP1Fanconi anaemia group J protein 17q22
Fanconi anaemia, complementation group A; FANCA 227650 AR FANCAFanconi anaemia group A protein 16q24.3
Fragile site mental retardation 1 309550 XL FMR1Fragile X mental retardation 1 protein Xq27.3
Fragile site, folic acid type, rare, FRA(X)(q28); FRAXE 309548 XL FMR2Fragile X mental retardation 2 protein Xq28 
Friedreich ataxia 1; FRDA 229300 AR FRDAFrataxin, mitochondrial precursor 9q13
Galactosaemia 230400 AR GALTGalactose-1-phosphate uridylyltransferase 9p13
Gangliosidosis, generalized GM1, type I 230500 AR GLB1 Galactosidase, beta 1 3p21.33 
Gaucher disease, type I 230800 AR GBAGlucosylceramidase [precursor] 1q21
Glomuvenous malformation (GVM) 138000 AD TIE2/TEK  1p22-p21
Glutaric acidaemia I 231670 AR GCDHGlutaryl-coenzyme A dehydrogenase 19p13.2
Glycogen storage disease type VI 232700 AR PYGLGlycogen phosphorylase, liver form 14q21-q22
Haemoglobin-alpha locus 1; HBA1 141800 AR HBA1Haemoglobin alpha chain 16pter-p13.3
Haemoglobin-alpha locus 2; HBA2 141850 AR HBA2Haemoglobin alpha subunit 16pter-p13.3
Haemoglobin-beta locus; HBB 141900 AR HBBHaemoglobin beta chain 11p15.5
Hemophagocytic lymphohistiocytosis, familial, 2 603553 AR PRF1Perforin 1 [precursor] 10q22
Hemophilia A 306700  XL F8Coagulation factor VIII [precursor] Xq28
Hemophilia B 306900 XL F9Coagulation factor IX [precursor] Xq27.1-q27.2 
HLA matching genotyping     6

Homocystinuria due to deficiency of N(5,10)-methylene tetrahydrofolate reductase activity

 236250 AR MTHFRMethylenetetrahydrofolate reductase 1p36.3
Hoyeraal−Hreidarsson syndrome; HHS 300240 XL DKC1H/ACA ribonucleoprotein complex subunit 4 Xq28
Huntington disease; HD 143100 AD HDHuntingtin 4 p16.3
Hurler syndrome 607014 AR IDUAAlpha-L-iduronidase [precursor] 4 p16.3
Hydrocephalus, X-linked; L1CAM 308840 XL L1CAM Neural cell adhesion molecule L1 [precursor] Xq28
Hyperinsulinemic hypoglycaemia, familial, 1; HHF1 256450 AR  ABCC8ATP-binding cassette, sub-family C (CFTR/MRP), member 8  11p15.1 
Hypophosphatasia, infantile 241500AR ALPL Alkaline phosphatase, tissue-non-specific isozyme [precursor] 1p36.1–34
Hypophosphatemic rickets, X-linked dominant 307800 XL PHEXPhosphate regulating endopeptidase homolog Xp22.2-p22.1 
Hypophosphatemic rickets, X-linked dominant 307800  XL PHEXPhosphate regulating endopeptidase homolog Xp22.2-p22.1 
Immunodeficiency with hyper-IgM, type 1; HIGM1 308230 XL TNFSF5Tumor necrosis factor ligand superfamily member 5 Xq26 
Incontinentia pigmenti; IP  308300 XL IKBKGNF-kappa-B essential modulator Xq28
Isovaleric acidaemia; IVA 243500 AR  IVDIsovaleryl coenzyme A dehydrogenase 15q14-q15
Krabbe disease 245200 AR GALC Galactocerebrosidase [precursor] 14q31
Leigh syndrome; LS 185620 AR SURF1Surfeit locus protein 1 9q34.2
Leukoencephalopathy with vanishing white matter; VWM 603896 AR EIF2B2Translation initiation factor eIF-2B beta subunit 14q24
Li−Fraumeni syndrome 1; LFS1 151623 AD TP53Cellular tumor antigen p53 17p13.1
Loeys−Dietz syndrome; LDS 609192 AD TGFBR2Transforming growth factor, beta receptor II (70/80kDa) 3p22
Long-chain 3-hydroxyacyl-coa dehydrogenase deficiency;HADHA 600890  AR HADHATrifunctional enzyme alpha subunit, mitochondrial [precursor] 2p 3
Machado−Joseph disease; MJD 109150 AD ATX3Machado−Joseph disease protein 1 14q24.3-q31
Marfan syndrome; MFS 154700 AD FBN1Fibrillin 1 [precursor] 15q21.1
Meckle-Gruber Syndrome 249000 AR MKS1  17q23
Metachromatic leukodystropy 250100 AR  ARSAArylsulfatase A [precursor] 22q13.31-qter
Metaphyseal chondrodysplasia, schmid type; MCDS 156500 AD COL10A1Collagen, type X, alpha 1 6q21-q22
Methylmalonic aciduria and homocystinuria (MMACHC) 277400 AR MMACHC  1p34.1 
Microcoria-congenital nephrosis syndrome 609049 AR LAMB2Laminin beta-2 3p21
Migraine, familial hemiplegic, 1; FHM1  141500 AD CACNA1ACalcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19p13.2-p13.1 
Morquio syndrome, non-keratosulfate-excreting type 252300 AR GALNSGalactosamine (N-acetyl)-6-sulfate sulfatase 16q24.3 
Mucopolysaccharidosis type II (Hunter) Hunter−McAlpine craniosynostosis syndrome 309900 AD IDS Iduronate 2-sulfatase [precursor] Xq28 
Multiple acyl-CoA dehydrogenase deficiency; MADD 231680  AR ETFAElectron-transfer-flavoprotein, alpha polypeptide 15q23-q25
Multiple endocrine neoplasia, type I; MEN1 131100 AD MEN1Multiple endocrine neoplasia I 11q13.1
Multiple endocrine neoplasia, type IIA; MEN2A 171400 AD  RETRet proto-oncogene 10q11.2
Muscular dystrophy, Becker type; BMD300376  XL DMD Dystrophin Xq21.2
Muscular dystrophy, Duchenne type; DMD 310200 XL DMDDystrophin Xq21.2
Myotubular myopathy 1; MTM1 310400 XL  MTM1Myotubularin Xq28
N-acetylglutamate synthase deficiency 237310 AR  NAGS N-acetylglutamate synthase 17q21.31
Neurofibromatosis, type I; NF1 162200 AD NF1Neurofibromin  17q11.2
Neurofibromatosis, type II; NF2 101000 AD NF2Merlin 22q12.2
Neuropathy, hereditary sensory and autonomic, type III; HSAN3 223900 AR IKBKAP Kinase complex-associated protein 9q31 
Niemann-Pick Disease 257220 AR NPC1  18q11-q12
Norrie disease; NDP 310600 XL NDPNorrin Xp11.4-p11.3
Oculocutaneous albinism, type I; OCA1 203100 AR TYRTyrosinase [precursor] 11q14-q21
Oculocutaneous albinism, type II; OCA2 203200 AD OCA2P protein 15q11.2-q12 
Omenn syndrome 603554 AD RAG1V(D)J recombination-activating protein 1 11p13 
Optic atrophy 1; OPA1 165500 AD OPA1Dynamin-like 120 kDa protein, mitochondrial [precursor] 3 q28-q29
Ornithine transcarbamylase deficiency 311250 XL OTCOrnithine carbamoyltransferase, mitochondrial [precursor] Xp21.1 
Osteogenesis imperfecta congenita; OIC 166200 AD COL1A2Collagen alpha 2(I) chain [precursor] 7 q22.1
Osteogenesis imperfecta congenita; OIC 166200 AD  COL1A1 Collagen alpha 1(I) chain [precursor]  17q21.31-q22
Osteopetrosis, autosomal recessive 259700 AR TCIRG1Vacuolar proton translocating ATPase 116 kDa subunit a isoform 3 11q13.4-q13.5.
Osteopetrosis, autosomal recessive 259700 AR TCIRG1T-cell, immune regulator 1 11q13.2
Pancreatitis, hereditary; PCTT 167800 AD PRSS1Protease, serine, 1 (trypsin 1) 7q32-qter|7q34
Pelizaeus−Merzbacher-like disease; PMLD 311601 XL PLP1Myelin proteolipid protein Xq22
Peutz−Jeghers syndrome; PJS 175200 AD STK11Serine/threonine kinase 11 19p13.3
Phenylketonuria 261600 AR PAHPhenylalanine-4-hydroxylase 12q22-q24.2
Polycystic kidney disease 1; PKD1 601313 AD PKD1Polycystin 1 precursor 16P13.3
Polycystic kidney disease 2; PKD2 173910 AD PKD2Polycystin 2 4 q22.1
Polycystic kidney disease, autosomal recessive; ARPKD 263200  AR PKHD1Polycystic kidney and hepatic disease 1 [precursor] 6 p12.3
Popliteal pterygium syndrome; PPS 119500
Interferon regulatory factor 6
Propionic acidaemia 232000 AR PCCAPropionyl coenzyme A carboxylase, alpha polypeptide 13q32
Retinitis pigmentosa 180380 AD RHORhodopsin 3q21-q24
Retinitis pigmentosa 3; RP3 300389 XL RPGRRetinitis pigmentosa GTPase regulator Xp21.1 
Retinoblastoma; RB1 180200 AD RB1Retinoblastoma-associated protein 13q14.1-q14.2 
Rett syndrome; RTT 312750 XL MECP2Methyl-CpG-binding protein 2 Xq28
Rhesus blood group, CcEe antigens; RHCE 111700 AD RHCECcEe antigens 1p36.2-p34
Rhesus blood group, D antigen; RHD 111680 AD RHDD antigen  1p36.11
Sandhoff disease 268800 AR HEXBBeta-hexosaminidase beta chain [precursor] 5 q13
Sickle cell anaemia 603903 AR HBBHaemoglobin beta chain 11p15.5
Smith−Lemli−Opitz syndrome; SLOS 270400 AR DHCR77-Dehydrocholesterol reductase 11q12-q13
Sonic hedgehog; SHH 600725 AD SHHSonic hedgehog protein [precursor] 7 q36
Spinal muscular atrophy, type I; SMA1 253300 AD SMN1Survival motor neuron protein 5 q12.2-q13.3
Spinocerebellar ataxia 1; SCA1 164400 AD ATXN1Ataxin 1 6p23
Spinocerebellar ataxia 2; SCA2 183090 AD ATX2SCA2 protein 12q24
Spinocerebellar ataxia 6; SCA6 183086 AD CACNA1AVoltage-dependent P/Q-type calcium channel alpha-1A subunit 19p13
Spinocerebellar ataxia 7; SCA7 164500 AD SCA7Ataxin-7 3 p21.1-p12
Stickler syndrome, type I; STL1 108300 AD COL2A1Collagen, type II, alpha 1 12q13.11-q13.2
Succinic semialdehyde dehydrogenase deficiency 271980 AR ALDH5A1Succinate semialdehyde dehydrogenase, mitochondrial [precursor] 6 p22
Symphalangism, proximal; SYM1 185800 AD NOGNoggin [precursor] 17q22
Tay-Sachs disease; TSD 272800 AR HEXABeta-hexosaminidase alpha chain [precursor] 15q23-q24 
Torsion dystonia 1, autosomal dominant; DYT1 128100 AD DYT1Torsin A [precursor] 9q34
Treacher Collins−Franceschetti syndrome; TCOF 154500 AD TCOF Treacle protein 5 q32-q33.1
Tuberous sclerosis type 1 191100 AD TSC1Hamartin 9q34
Tuberous sclerosis type 2 191100 AD TSC2Tuberin 16p13.3
Tyrosinaemia, type I 276700 AR FAHFumarylacetoacetate hydrolase (fumarylacetoacetase) 15q23-q25
Ulnar−mammary syndrome; UMS 181450 AD TBX3T-box 3 12q24.1
Von Hippel−Lindau syndrome; VHL 193300 AD VHLVon Hippel−Lindau disease tumor suppressor 3 p26-p25
Wiskott−Aldrich Syndrome; WAS 301000 XL WASWiskott−Aldrich syndrome protein  Xp11.23-p11.22
Zellweger syndrome; ZS 214100 AR PXMP3Peroxisomal membrane protein 3, 35kDa 8q21.1
Zellweger syndrome; ZS 214100 AR PEX1 Peroxisome biogenesis factor 1 7 q21-q22 


Specific Diagnosis for X-linked Diseases

More than one half of PGD cases for single gene disorders were performed by gender determination for X-linked conditions, which were the most straightforward application from the very beginning, either using PCR or FISH technique.5, 7 This was not only because the sequence information was not always available but also because it was technically easier to identify female embryos by DNA analysis or FISH technique, despite the obvious cost of discarding 50% healthy male embryos. However, testing for X-linked genetic disorders may be entirely limited to oocytes, because the mutations involved are fully maternally derived. Therefore, testing of oocytes for maternally derived specific mutations makes it possible to avoid further testing of the resulting embryos, which may be transferred irrespective of gender or any contribution from the father. Initially, the approach was applied for ornithine transcarbamylase deficiency (OTC)26 and then was extended to specific diagnosis of other X-linked disorders,11 and presently comprises the experience of specific diagnosis in a few dozens of clinical cycles performed for OTC, XMR1, myotubular myotonic dystrophy and X-linked hydrocephalus. This resulted in transfer of mutation free embryos in almost all cycles and yielding dozens unaffected clinical pregnancies. Specific diagnosis for X-linked mutations has also been performed at the cleavage stage.27, 28 The data demonstrate the clinical usefulness of the specific polar body or blastomere testing for X-linked disorders as an alternative to PGD by gender determination.


Couples with Homozygous Affected Partners

PGD was also provided for couples with one homozygous or double heterozygous-affected partner who were affected patients with thalassemia or phenylketonuria (PKU), resulting in an unaffected pregnancy and birth of healthy children.1, 2, 29 Although the risk for producing an affected child in such couples is as high as 50%, irrespective of maternal or paternal affected status, the strategy of PGD in such cases will depend on whether father or mother is affected. In couples with the affected fathers, PGD may concentrated on the preselection of mutation-free oocytes, while with the affected mothers, a cleavage stage PGD is required to identify those few embryos containing the normal gene.

The testing is particularly complicated if the parents are carrying different mutations. In one such case performed for thalassemia, the affected mother was double heterozygous (IVS I-110; IVS I-1-6) while the male partner was heterozygous carrier of the third mutation (IVS II-745).1, 25 This required a complex PGD design to exclude preferential amplification of each of the three alleles tested in blastomeres that underwent biopsy (Fig. 11), as also described in PGD for PKU.29 In this case, the affected father was compound heterozygous for R408 and Y414C mutations in exon 12 of phenylalanine hydroxylase (PAH) gene, and the carrier mother was heterozygous for R408W mutation in the same exon. PGD strategy was based on the preselection of the mutation-free oocytes using a sequential PB1 and PB2 DNA analysis. Based on the multiplex heminested PCR analysis, four embryos resulting from the zygotes predicted to contain no mutant allele of PHA gene were transferred, yielding an unaffected twin pregnancy and birth of the healthy twins (Fig. 12).

Figure 11. PGD analysis for three different mutations in beta-globin gene in a couple with homozygous-affected female partner

Fig. 12. PGD for R408W in phenylalanine hydroxylase gene


With the improvement of treatment and improved life expectancy for increasing number of genetic disorders, an increasing number of couples with affected maternal or paternal partners may require PGD as the only means for having unaffected children of their own.


Cancer Predisposition

Cancer predisposition has not traditionally been considered as an indication for prenatal diagnosis, because this would lead to pregnancy termination, which is not justified on the basis of genetic predisposition alone. However, the possibility of choosing embryos free of genetic predisposition for transfer would obviate the need for considering pregnancy termination, because only potentially normal pregnancies are established. PGD for such conditions appears acceptable on ethical grounds because only a limited number of the embryos available from hyperstimulation are selected for transfer.

The first PGD for inherited cancer predisposition have been performed for couples carrying p53 tumor-suppressor gene mutations known to determine a strong predisposition to the majority of cancers.30 The couple was with the paternally derived missense mutation caused by a transversion of a G-to-A in exon 5 of the p53 tumor-suppressor gene. The carrier was a 38-year-old proband with Li-Fraumeni syndrome (LFS), diagnosed with rhabdomyosarcoma of the right shoulder at the age of 2 followed by right upper extremity amputation. At the age of 31, he was also diagnosed with a high-grade leiomyosarcoma of the bladder and underwent a radical cystoprostatectomy. His mother was diagnosed with leiomyosarcoma at age 37.

PGD was performed by blastomere biopsy and multiplex nested PCR analysis with simultaneous testing for p53 tumor-suppressor gene mutation and linked polymorphic markers, allowing preselecting and transferring back to the patient only mutation-free embryos (Fig. 13). A singleton pregnancy and birth of a mutation-free child resulted, and the child is currently healthy and free from the mutation predisposing to LFS.

Fig. 13. PGD for p53 tumor-supressor gene mutations


At present, PGD is also applied for other cancers, including familial adenomatous polyposis coli, Von Hippel Lindau syndrome, retinoblastoma, neurofibromatosis types I and II, and familial posterior fossa brain tumor.31 A few dozens of PGD cycles were performed, resulting in preselection and transfer of mutation- free embryos in the majority of them, which yielded unaffected clinical pregnancies and birth of healthy children. Despite the controversy of PGD use for late-onset disorders, the data demonstrate the usefulness of this approach as the only acceptable option for at-risk couples to avoid the birth of children with inherited predisposition to cancer and to have a healthy child (for the updated experience see25).


Other Late-Onset Disorders With Genetic Predisposition

One of the first experiences of PGD for late-onset disorders was PGD for genetic predisposition to one of the forms of Alzheimer disease (AD)32 caused by an autosomal-dominant familial predisposition to a presenile form of dementia, determined by nearly completely penetrant autosomal-dominant mutation in the amyloid precursor protein (APP) gene, for which no treatment is available despite a possible predictive diagnosis. A 30-year-old women had no signs of AD but was a carrier of V717L mutation, resulting from G-to-C substitution in exon 17 of the APP gene. The predictive testing in the patient was performed because of the early-onset AD in her sister carrying this mutation in whom symptoms of AD developed at age 38. This sister is still alive, but her cognitive problems progressed to the point that she was placed in an assisted living facility. Her father had died at age 42 and also had a history of psychological difficulties and marked memory problems. V717L mutation was also detected in one of her brothers who experienced mild short-term memory problems as early as age 35, with a moderate decrease in memory, new learning, and sequential tracking over the next 2–3 years. The other family members, including one brother and two sisters, were asymptomatic, although predictive testing was performed only in sisters, who appeared to be free from mutation in APP gene (Fig. 14).

Figure 14. Pedigree of family with early-onset Alzheimer disease determined by mutation V717L

PGD was performed by DNA analysis of PB1 and PB2 to preselect and transfer back to the patient only the embryos resulting from mutation-free oocytes. Based on both mutation and the linked marker analysis, unaffected embryos resulting from mutation-free oocytes were preselected for transfer back to the patients, resulting in a singleton clinical pregnancy and birth of an unaffected mutation-free child.

PGD, therefore, provides a nontraditional option for patients who may wish to avoid the transmission of the mutant gene predisposing to the late-onset disorders in their potential children. Because such diseases present beyond early childhood or later and may not be expressed in 100% of the cases, the application of PGD for this group of disorders is still controversial. However, for diseases with no current prospect for treatment arising despite presymptomatic diagnosis and follow-up, PGD may be offered as the only relief for the at-risk couples (for the updated experience see 25).


Blood Group Incompatibility

The first PGD for maternal–fetal incompatibility resulting in the healthy pregnancy outcome was performed for Kell (K1) genotype, which is one of the major antigenic systems in human red blood cells, comparable in importance with RhD, causing maternofetal incompatibility leading to severe hemolytic disease of the newborn (HDN) in sensitized mothers.33 K1 allele is present in 9% of the populations, in contrast to its highly prevalent allelic variant K2. The gene is located on chromosome 7 (7q33), consisting of 19 exons with the only C-to-T base substitution in exon 6 in K1 compared with K2 antigen.

In cases of pregnancy by the K1 fetus in the K2 mother, antibodies to K1 may be developed, leading to maternofetal incompatibility causing severe HDN. Although prenatal diagnosis is available for identification of pregnancies at risk for HDN, this may not always prevent the potential complications for the fetus, such as stillbirth or neonatal death, making PGD a possible option for preventing both Kell and Rhesus hemolytic diseases.

PGD for Kell disease was performed for two at-risk couples with a history of neonatal death in previous pregnancies caused by HDN. The preselection and transfer of the embryos free from K1 allele of KEL gene was possible in each case, yielding a clinical pregnancy and the birth of healthy twins, confirmed to be free of K1 allele (Fig. 15).

Fig. 15. PGD for Kell genotype (pedigree)


A number of attempts have also been undertaken to perform PGD for Rhesus disease, which, however, has not yet resulted in a clinical pregnancy.34 Both of these conditions are quite prevalent, taking into consideration the approximately 15% frequency for RhD and 9% for KEL antigen, presenting the risk for alloimmunization that may lead to HDN in some of the at-risk couples. Therefore, PGD may be a useful option for these couples to avoid the establishment of the RhD or K1 pregnancy in the sensitized mothers.

Although the at-risk pregnancies detected by prenatal diagnosis may be treated by an intrauterine transfusion, the potential complication for the fetus cannot be completely excluded even after this procedure. Pregnancy termination in such cases will also be unacceptable, because the antibodies to K1, for example, are developed only in 5% of persons obtaining incompatible blood. However, some of the at-risk couples have had such unfortunate experience with HDN, resulting in neonatal death as in both of our couples, that they regard PGD as their only option to plan another pregnancy. This makes PGD attractive for patients at risk for alloimmunization, although such conditions have rarely been an indication for prenatal diagnosis.


Congenital Malformations

Congenital malformations are highly prevalent (29.3/1000 live births) and are usually sporadic. However, with progress of the human genome project, an increasing number of inherited forms are being described, which therefore may be avoided through PGD. For example, sonic hedgehog (SHH) gene mutation, for which the first PGD has recently been performed,22 causes the failure of cerebral hemispheres to separate into distinct left and right halves and leads to holoprosencephaly (HPE), which is one of the most common developmental anomalies of forebrain and midface. Although most HPE are sporadic, familial cases are not rare, with clear autosomal-dominant inheritance.

A great intrafamilial clinical variability of HPE from alobar HPE and cyclopia, to cleft lip and palate, microcephaly, ocular hypertelorism, and even normal phenotype, suggests the interaction of SHH gene with other genes expressed during craniofacial development and the possible involvement of environmental factors. This may explain the fact that almost one third of carriers of SHH mutations may be clinically unaffected. Therefore, even in familial cases, the detection of SHH mutations in prenatal diagnosis might not justify pregnancy termination, making PGD a more attractive option for couples at risk for producing a progeny with HPE, as demonstrated in the first PGD for this mutation.22

This couple presented for PGD because of the previous two children with the clinical signs of HPE. One of them, a female with severe HPE and cleft lip and palate, died soon after birth. Both the child and the parents were chromosomally normal, but DNA analysis in the child's autopsy material demonstrated the presence of SHH nonsense mutation caused by GAG-to-TAG sequence change, leading to premature termination of the protein at position 256 (Glu256 → stop). The same mutation was found in their 5-year-old son who was born after a full-term normal pregnancy. This child has less severe facial dysmorphisms, which included microcephaly, Rathke's pouch cyst, single central incisor, and choanal stenosis. There was also clinodactyly of the fifth fingers and curved-in fourth toes bilaterally. The child's growth was slow in the first 2 years, but thereafter he has been maintaining a reasonably good growth (Fig. 16).

Figure 16. PGD for sonic hedgehog (SHH) mutation: family pedigree


PGD was performed by blastomere biopsy and multiplex nested PCR analysis involving specific mutation testing simultaneously with linked marker analysis (Table 3). Of nine tested embryos, four embryos were free of mutant gene, from which two were transferred back to patient, resulting in a singleton pregnancy and birth of a healthy child after confirmation of the mutation-free status by amniocentesis (see Fig. 16). Similar approach was used for PGD of Crouson syndrome.35

The data suggest the clinical usefulness of PGD for familial cases of congenital malformations. Because of high prevalence of congenital anomalies, the approach may have practical implications for the at-risk couples as a preventive measure to be used in genetic practices (for the updated experience see25).


Preimplantation HLA Matching Combined With PGD

Preimplantation HLA-matching was first introduced in combination with mutation analysis for Fanconi anemia with the objective of establishing an unaffected pregnancy yielding a potential donor progeny for transplantation in an affected sibling.36 This resulted in a clinical pregnancy and birth of an unaffected child whose cord blood was transplanted to the affected sibling, thus saving her life (Fig. 17).

Fig. 17. HLA detection system by allele-specific primers in case of PGD for Fanconi anemia


The strategy would not likely be clinically acceptable through traditional prenatal genetic diagnosis because of a possible clinical pregnancy termination after HLA-matching. However, PGD for such purpose should be acceptable, because only a limited number of the embryos are usually preselected for transfer, which in this case will represent unaffected embryos with a perfect match for affected siblings in need of transplantation. Because the multiplex single cell PCR used in PGD presents the opportunity for combined PGD and HLA testing, it has become a useful way to preselect an embryo that may be an HLA-match to the affected sibling requiring stem cell transplantation.

The method has currently been applied for the HLA-genotyping in two dozen cycles in combination with PGD for thalassemia, Fanconi anemia, hyper immunoglobulin M syndrome, X-linked adrenoleukodystrophy, and Wiskott-Aldrich syndrome, confirming the usefulness of preimplantation HLA-matching as part of PGD, with prospect of application of this approach to other inherited conditions also requiring an HLA-compatible donor for bone marrow transplantation.18, 25, 37, 38, 39, 40, 41, 42 This provides a realistic option for the couples desiring to avoid the birth of an affected child, together with the establishment of a healthy pregnancy, potentially providing an HLA-matched progeny for treatment of an affected sibling.



Important ethical issues have been raised with an increasing use of PGD for late onset disorders with genetic predisposion and preimplantation HLA typing to produce an HLA compatible donor for treating a family member with fatal bone marrow disease or cancer, requiring a stem cell transplantation.43, 44, 45, 46, 47 Although there is no actual difference in the application of PGD for the latter conditions, the controversy can be explained by the fact that in traditional prenatal diagnosis if the fetus would be found to carry the gene predisposing to late-onset disorder or to be HLA unmatched, the couple would have to make an extremely difficult decision of pregnancy termination, which could hardly be justified by such findings. Alternatively, PGD technology allows genetic testing of human eggs and embryos before pregnancy is established, making totally realistic to establish only HLA matched or potentially normal pregnancies without genetic predisposition to late onset common disorders.

In any case, as seen from this review, PGD is now becoming an established clinical option in reproductive medicine and is applied using separate consent forms and the research protocols approved by Institutional Ethics Committees. The number of apparently healthy children born after PGD is now a few thousand, showing that there is no evidence of any incurred adverse effect. However, these protocols would still require confirmatory CVS or amniocentesis and a follow-up monitoring of its safety and accuracy. Although PGD will help solve some of the long-standing ethical problems, such as the abortion issue (which will be avoided as a result of this new approach), others could become a serious obstacle, particularly those related to designer babies. These considerations are highly relevant to the subject of PGD, as well as to any other new methods as we proceed with further development of appropriate technology for controlling genetic disability.



Verlinsky Y, Kuliev A: Atlas of Preimplantation Genetic Diagnosis. London, NY, Parthenon Publishing Group, 2000



Verlinsky Y, Kuliev A. Atlas of Preimplantation Genetic Diagnosis. Taylor and Francis, London, N.Y, 2005



Verlinsky Y, Cohen J, Munne S, Gianaroli L, Simpson JL, Ferraretti AP, Kuliev A. Abstract. Over a decade of experience with preimplantation genetic diagnosis: a multicenter report. Fertil Steril. 2004 Aug;82(2):292-4.



Kuliev A, Verlinsky Y. 2008 Technological developments in preimplantation genetic diagnosis to improve the accuracy and range. Reproductive BioMedicine Online 5, 296-301.



International Working Group on Preimplantation Genetics (IWGPG): Preimplantation Genetic Diagnosis--Experience of Three Thousand Clinical Cycles. Report of the 11th Annual Meeting International Working Group on Preimplantation Genetics, in conjunction with 10th International Congress of Human Genetics, Vienna, May 15, 2001 Reprod BioMed Online 3:49-53, 2001



Kuliev A, Verlinsky Y: Current features of preimplantation genetic diagnosis. Reprod BioMed Online 5:296-301, 2002



ESHRE Preimplantation Genetic Diagnosis Consortium: Data Collection III, May 2002. Hum Reprod 17:233-246, 2002



Preimplantation Genetic Diagnosis International Society (PGDIS) 2008 Guidelines for good practice in PGD: program requirements and laboratory quality assurance. Reproductive BioMedicine Online 16, 134-147



Rechitsky S, Verlinsky O, Amet T et al: Reliability of preimplantation diagnosis for single gene disorders. Mol Cell Endocrinol 183:S65-S68, 2001



Rechitsky S, Strom C, Verlinsky O et al: Allele drop out in polar bodies and blastomeres. J Assist Reprod Genet 15:253-257, 1998



Verlinsky Y, Rechitsky S, Verlinsky O et al: Polar body based preimplantation diagnosis for X-linked genetic disorders. Reprod BioMed Online 4:38-42, 2002



Kuliev A, Rechitsky S, Verlinsky O et al: Birth of healthy children after reimplantation diagnosis of thalassemias. J Assist Reprod Gent 16:207-211, 1999



Rechitsky S, Verlinsky O, Kuliev A et al: Preimplantation genetic diagnosis for familial dysautonomia. Reprod BioMed Online 6:488-496, 2003



Sermon K, Seneca S, De Rycke M et al: PGD in the lab for triplet diseases-myotonic dystrophy, Huntington's disease and Fragile-X syndrome. Mol Cell Endocrinol 183:S77-S85, 2001



Katz MG, Mansfield J, Gras L et al: Diagnosis of trisomy 21 in preimplantation embryos by single-cell DNA fingerprinting. Reprod BioMed Online 4:43-50, 2002



Harper J, Wells D, Piyamongkol W et al: Preimplantation genetic diagnosis for single gene disorders: experience with five single gene disorders. Prenat Diagn 22:525-533, 2002



Ray PF, Frydman N, Attie T et al: Birth of healthy twins after preimplantation diagnosis of Cystic fibrosis combined with gender determination. Mol Hum Reprod 8:688-694, 2002



Verlinsky Y, Rechitsky S, Verlinsky O, Ozen S, Beck R, Kuliev A. 2004a Preimplantation genetic diagnosis for polycystic kidney disease PKD Fertil Steril 82:926-929



Alterescu G, Brooks B, Margalioth EJ, Eldar-Geva T, Levy-Lahad E, Renbaum P 2007 Simultaneous preimplantation genetics diagnosis for Tay Sachs and Gaucher disease. Reproductive BioMedicine Online 15, 83-88



Treff NR, Su J, Mavrianos J, Bergh PA, Miller KA, Scot RT. 2007 Accurate 23 chromosome aneuploidy screening in human blastomeres using single nucleotide polymorphism (SNP) microarrays. Fertil Steril 88 (Suppl 1), S1



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for long-chain 3-hydroxyacyl-coa dehydrogenase deficiency. Reprod BioMed Online 2:17-19, 2001



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation Diagnosis for Sonic Hedgehog Mutation Causing Familial Holoprosencephaly. N Engl J Med 348:1449-1454, 2003



International Working Group on Preimplantation Genetics (IWGPG): Tenth Anniversary of Preimplantation Genetic Diagnosis: Report of the 10th Annual Meeting International Working Group on Preimlantation Genetics, in association with 3rd International Symposium on Preimplantation Genetics, Bologna, Italy, June 23, 2000. J Assist Reprod Genet 18:66-72, 2001



Kuliev A, Rechitsky S, Verlinsky Y. 2007 Preimplantation Diagnosis. Nature Encyclopedia of Life Sciences. A002507



Verlinsky Y. and Kuliev A. 2006 Practical Preimplantation Genetic Diagnosis. Springer, London, N.Y



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for ornithine transcarbamilase deficiency. Reprod BioMed Online 1:45-47, 2000



Ray P, Harper J, Ao A et al: Successful preimplantation genetic diagnosis for sex linked Lesch-Nyhan syndrome using specific diagnosis. Prenat Diagn 19:1237-1241, 1999



Ray PF, Gigarel N, Bonnefont JP et al: First specific preimplantation genetic diagnosis for ornithine transcarbamylase deficiency. Prenat Diagn 20:1048-1054, 2000



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for PKU. Fertil Steril 76:346-349, 2001



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for p53 tumor suppressor gene mutations. Reprod BioMed Online 2:102-105, 2001



Rechitsky S, Verlinsky O, Chistokina A et al: Preimplantation genetic diagnosis for cancer predisposition. Reprod BioMed Online 5:148-155, 2002



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for early onset Alzheimer disease Caused by V717L Mutation. J Am Med Assoc 287:1018-1021, 2002



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for Kell genotype. Fertil Steril 80:1047-1051, 2003



Van Den Veyver IB: Prenatal and Preimplantation Genetic Diagnosis for RhD Alloimmunization, pp 181–185. 10th International Conference on Prenatal Diagnosis and Therapy. Barcelona (Spain), June 19–21, 2000. Barcelona, University of Barcelona, 2000



Abou-Sleiman PM, Apessos A, Harper JC et al: Pregnancy following preimplantation genetic diagnosis for Crouson syndrome. Mol Hum Reprod 8:304-309, 2002



Verlinsky Y, Rechitsky S, Verlinsky O et al: Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA 285:3130-3133, 2001



Rechitsky S, Kuliev A, Tur-Kaspa I, Morris R, Verlinsky Y. 2004 Preimplantation HLA typing with preimplantation genetic diagnosis. Reproductive BioMedicine Online 6:488-493.



Kahraman S, Karlilaya G, Sertyel S, Karadayi H, Findicli N, Oncu N. 2004 Clinical Aspects of Preimplantation Genetic Diagnosis of Single Gene Disorders Combined with HLA Typing. Reproductive BioMedicine Online 9: 529-532.



Van deVelde H, Georgiou I, De Rycke M et al. 2004 Novel universal approach for preimplantation genetic diagnosis of β-thalassemia in combination with HLA matching of embryos. Hum Reprod 19:700-708



Kuliev A, Rechitsky S, Verlinsky O, et al. 2005. Preimplantation diagnosis and HLA typing for hemoglobin disorders. Reproductive BioMedicine Online 11: 362-370



Rechitsky S, Kuliev A, Sharapova T, et al. 2006 Preimplantation HLA typing with aneuploidy testing. Reprod BioMedicine Online 12: 81-92.



Verlinsky Y, Rechitsky S, Sharapova T et al. 2006 Preimplantation diagnosis for immnudeficiencies. Reprod BioMed Online 4, 38-42



Damewood MD: Ethical implications of a new application of preimplantation diagnosis. JAMA 285:3143-3144, 2001



Towner D, Loewy RS: Ethics of preimplantation diagnosis for a woman destined to develop early-onset Alzheimer disease. JAMA 287:1038-1040, 2002



Edwards RG: Social and ethical issues of PGD, cloning and gene therapy. Reprod BioMed Online 6:170-180, 2003



Robertson JA: Extending preimplantation genetic diagnosis: the ethical debate. Hum Reprod 18:465-471, 2003



Edwards RG. Ethics of PGD: thoughts on the consequences of typing HLA in embryos. Reproductive BioMedicine Online 2004; 9:222-224.

Back to Top